BioSpace News Archive

Business

9 Top M&As in the First Half of 2023

Despite a challenging economic climate and gloomy forecast, 2023 has still notched some mega-deals for biopharmas. BioSpace highlights the biggest deals in the industry this year.

June 28, 2023
·
5 min read
·
Lisa Munger
Policy

FDA Blocks Regeneron’s Bid for Higher Eylea Dose

Citing issues with a third-party contractor, the FDA rejected Regeneron’s regulatory application for a higher-dose regimen of Eylea, the company’s blockbuster eye injection treatment.

June 28, 2023
·
2 min read
·
Tristan Manalac
Policy

EEOC Prevails Over Lilly in Age Discrimination Suit, Reaching Settlement

The U.S. Equal Employment Opportunity Commission settled with Eli Lilly for $2.4 million after filing a suit in September over the company’s recruitment of younger workers.

June 28, 2023
·
2 min read
·
Lisa Munger
FDA

Pfizer, OPKO Get FDA Nod for Pediatric Growth Hormone Deficiency Drug

Overcoming an FDA rejection in January 2022, Pfizer and OPKO’s Ngenla will provide a long-acting, reduced-frequency treatment option for children with growth hormone deficiency.

June 28, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Bayer’s BlueRock Reports Positive Early Data for Parkinson’s Stem Cell Therapy

While early, the Phase I study results for 12 patients represent a promising return on Bayer’s investment in BlueRock, which it launched with Versant Ventures in 2016 and fully acquired three years later.

June 28, 2023
·
2 min read
·
Heather McKenzie
Policy

9 Highly Anticipated FDA Decisions in the Second Half of 2023

After a series of milestone approvals in the first half of 2023, the FDA is slated to decide on four more firsts before the year’s end.

June 28, 2023
·
7 min read
·
Heather McKenzie
Employer Resources

How to Support Working Parents Without Alienating Child-Free Staff

Providing extra benefits and perks to parents in the workplace can be polarizing, but it doesn’t have to be.

June 28, 2023
·
4 min read
·
Rosemary Scott
Business

Gates Foundation, Wellcome Pledge $550M for Phase III Trial of GSK’s TB Vaccine

The funds will support a trial of a tuberculosis vaccine developed by GSK that could potentially be the first new TB shot in a century.

June 28, 2023
·
2 min read
·
Connor Lynch
Biotech Bay

Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain

Mainz Biomed NV, a molecular genetics diagnostic company specializing in early cancer detection, is thrilled to announce its participation in the highly anticipated ESMO World Congress on Gastrointestinal Cancer 2023.

June 28, 2023
·
5 min read
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research

ExeVir Bio announced it has been awarded a two-year R&D grant of EUR 1.6 million by Flanders Innovation & Entrepreneurship for pre-clinical research towards prophylactic and therapeutic solutions for dengue.

June 28, 2023
·
5 min read